Good day, ladies and gentlemen. Welcome to the BioMarin Pharmaceutical Inc. Fourth Quarter and Full Year 2012 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. ...
Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2011 BioMarin Pharmaceutical Earnings Conference Call. My name is Jeremy and I'll be your operator for today. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session.
Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2010 BioMarin Pharmaceutical Incorporated Earnings Conference Call. My name is Jonathan, and I'll be your operator for today. At this time, all participants are in a listen-only mode. We will be conducting a question-and-answer session towards the end of this conference. (Operator Instructions). As a reminder, this conference call is being recorded for replay purposes.
Good day, ladies and gentlemen, and welcome to the Quarter Three 2010 BioMarin Pharmaceutical Financial Results Conference Call. My name is Jennifer and I'll be your operator for today. At this time, all participants are on a listen-only mode. We will conduct a question-and-answer session towards ...
Good day, ladies and gentlemen, and welcome to the Second Quarter 2012 BioMarin Conference Call. My name is Chanel and I'll be your operator for today. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.